Neurocrine Biosciences, Inc. (NBIX)

Market Cap	11.29B
Revenue (ttm)	2.36B
Net Income (ttm)	341.30M
Shares Out	99.70M
EPS (ttm)	3.29
PE Ratio	34.41
Forward PE	17.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	762,382
Open	113.36
Previous Close	114.00
Day's Range	112.21 - 113.69
52-Week Range	105.18 - 157.98
Beta	0.35
Analysts	Buy
Price Target	166.75 (+47.27%)
Earnings Date	Apr 30, 2025

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 1996
• Employees: 1,800
• Stock Exchange: NASDAQ
• Ticker Symbol: NBIX
• Website: https://www.neurocrine.com

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Analyst Forecast

According to 21 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $166.75, which is an increase of 47.27% from the latest price.

Price Target

$166.75

(47.27% upside)

Analyst Consensus: Buy